CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 307 enrolled
Drug / intervention
CyberKnife Stereotactic Radiosurgery - Low Risk +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00643617
NCT00643617N/ACompleted
CompareCT.gov

Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Accuray Incorporated·interventional·Posted Mar 26, 2008·Updated May 9, 2023

In Brief

A clinical study evaluating CyberKnife Stereotactic Radiosurgery - Low Risk and CyberKnife Stereotactic Radiosurgery - Intermediate Risk for Prostate Cancer and 4 related conditions. Completed, enrolled 307 participants across 18 sites.

Detailed Summary

The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms, Cancer of the Prostate
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2008
Enrollment StartOct 22, 2007
Primary CompletionApr 7, 2022
TodayJul 2, 2026
Enrollment to primary: 14.5 yearsPosted 18.3 years ago

Interventions

CyberKnife Stereotactic Radiosurgery - Low Riskradiation

38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate

CyberKnife Stereotactic Radiosurgery - Intermediate Riskradiation

38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally